Medtronic MiniMed Paradigm Recall Issued for Insulin Infusion Sets

A class I recall has been issued for insulin infusion sets, after a problem was detected that may cause Medtronic MiniMed Paradigm pumps to administer too much or too little insulin, which could cause serious or even fatal health consequences for diabetics.

The Medtronic MiniMed Paradigm Insulin Infusion Set recall was announced by the U.S. Food and Drug Administration on June 7, due to an issue where fluids may come in contact with the tubing connector of the MiniMed Paradigm pumps. If the vents become blocked, the pump may not prime itself properly, causing the device not to work properly.

Due to the serious risk posed for diabetics who rely in the infusion pump to maintain acceptable blood glucose levels, the FDA has categorized an urgent medical device safety notification issed by Medtronic on June 7 as a “Class I recall,” suggesting that continued use of the infusion sets poses a reasonable risk of serious adverse health consequences or death.

Learn More About

Medtronic MiniMed Lawsuits

Recalled Medtronic MiniMed insulin pumps have been linked to reports of hypoglycemia, hyperglycemia and other serious injuries.

Learn More About this Lawsuit SEE IF YOU QUALIFY FOR COMPENSATION

The recall affects Medtronic MiniMed Paradigm Insulin Infusion Sets manufactured from October 2001 through June 2013, which were distributed from December 2001 through June 2013, including the following Medtronic models; MMT-317, MMT-318, MMT-324, MMT-325, MMT-312S, MMT-312L, MMT-386, MMT-387, MMT-394, MMT-396, MMT-397, MMT-398, MMT-399, MMT-377, MMT-378, MMT-381, MMT-382, MMT-383, MMT-384, MMT-368, MMT-862, MMT-864, MMT-866, MMT-874, MMT-876, MMT-884, MMT-886, MMT-921, MMT-923, MMT-925, MMT-941, MMT-943, MMT-945, MMT-961, MMT-963, MMT-965, & MMT-975 Paradigm Infusion sets.

In 2009, Medtronic Inc. issued a similar recall for approximately three million Quick-set infusion sets used with its MiniMed Paradigm insulin pumps, due to a manufacturing defect that could result in the delivery of incorrect doses of insulin and cause injury or death for diabetics using the Medtronic insulin pumps.

Following that recall, a number of Medtronic infusion set lawsuits were filed on behalf of patients of suffered serious injury or death when they received too much or too litte insulin.

In this latest recall, the FDA has indicated that patients should be on the lookout for signs that may indicator the connector vents on the infusion sets are not working properly. Patients have been advised that if they notice anything unusual during the infusion set prime process, such as insulin continuing to drip from the top of the infusion set cannula, they should not insert the infusion set and should call a HelpLine established at 1-888-204-7616.

Tags:
Image Credit: |

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.